Tissue factor (TF) is expressed at very high levels on tumors and their blood vessels (vasculature) in a broad range of solid tumors – including head and neck, cervical, pancreas, prostate, esophageal, gastric and non-small cell lung tumors.

While TF overexpression itself is not oncogenic, it facilitates key processes that lead to the development and progression of tumors, including angiogenesis (abnormal blood vessel formation) and metastasis. Tumors that overexpress TF are highly aggressive and malignant and are associated with a poor prognosis.

Recent clinical data have demonstrated preliminary activity with an investigational anti-TF agent in a subset of cancer patients, suggesting that TF is a high potential target in oncology.